LitCovid-sample-Enju  

PMC:7228307 / 54063-59627 JSONTXT 23 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T0 3288-3291 DT denotes The
T1 3292-3302 NN denotes expression
T2 3303-3305 IN denotes of
T3 3306-3313 NN denotes FcγRIIb
T4 3314-3316 IN denotes on
T5 3317-3321 NNP denotes LSEC
T6 3322-3325 CC denotes and
T7 3326-3329 PRP-DOLLAR- denotes its
T8 3330-3336 NN denotes action
T9 3337-3339 IN denotes in
T10 3340-3343 DT denotes the
T11 3344-3354 NN denotes “sweeping”
T12 3355-3357 CC denotes or
T13 3358-3365 NN denotes removal
T14 3366-3368 IN denotes of
T15 3369-3374 JJ denotes small
T16 3375-3381 JJ denotes immune
T17 3382-3391 NNS denotes complexes
T18 3392-3395 VBZ denotes has
T19 3396-3402 VBN denotes opened
T20 3403-3405 RP denotes up
T21 3406-3409 JJ denotes new
T22 3410-3423 NNS denotes possibilities
T23 3424-3427 IN denotes for
T24 3428-3431 DT denotes the
T25 3432-3443 NN denotes application
T26 3444-3446 IN denotes of
T27 3447-3464 VBG denotes FcγRIIb‐enhancing
T28 3465-3481 NN denotes modifications.17
T29 3482-3492 NNS denotes Antibodies
T30 3493-3495 CC denotes or
T31 3496-3498 NN denotes Fc
T32 3499-3505 NN denotes fusion
T33 3506-3514 NNS denotes proteins
T34 3514-3515 -COMMA- denotes ,
T35 3516-3521 WP-DOLLAR- denotes whose
T36 3522-3529 JJ denotes primary
T37 3530-3533 NN denotes MOA
T38 3534-3536 VBZ denotes is
T39 3537-3540 DT denotes the
T40 3541-3555 NN denotes neutralization
T41 3556-3558 IN denotes of
T42 3559-3566 JJ denotes soluble
T43 3567-3576 NNS denotes molecules
T44 3577-3581 JJ denotes such
T45 3582-3584 IN denotes as
T46 3585-3588 NN denotes IgE
T47 3589-3591 CC denotes or
T48 3592-3601 NNS denotes cytokines
T49 3601-3602 -COMMA- denotes ,
T50 3603-3606 VBP denotes are
T51 3607-3619 RB denotes particularly
T52 3620-3630 JJ denotes attractive
T53 3631-3641 NNS denotes candidates
T54 3642-3645 IN denotes for
T55 3646-3650 DT denotes this
T56 3651-3659 NN denotes approach
T57 3661-3677 NN denotes Proof‐of‐concept
T58 3678-3681 IN denotes for
T59 3682-3686 DT denotes this
T60 3687-3695 NN denotes strategy
T61 3696-3699 VBZ denotes has
T62 3700-3704 VBN denotes been
T63 3705-3717 VBN denotes demonstrated
T64 3718-3720 IN denotes in
T65 3721-3733 JJ denotes experimental
T66 3734-3743 NN denotes models.48
T67 3744-3750 RB denotes Indeed
T68 3750-3751 -COMMA- denotes ,
T69 3752-3756 DT denotes this
T70 3757-3760 MD denotes may
T71 3761-3763 VB denotes be
T72 3764-3765 DT denotes a
T73 3766-3777 JJ denotes significant
T74 3778-3787 NN denotes component
T75 3788-3790 IN denotes of
T76 3791-3794 DT denotes the
T77 3795-3800 JJ denotes rapid
T78 3801-3814 NN denotes disappearance
T79 3815-3817 IN denotes of
T80 3818-3821 NN denotes IgE
T81 3822-3826 IN denotes from
T82 3827-3830 DT denotes the
T83 3831-3842 NN denotes circulation
T84 3843-3845 IN denotes of
T85 3846-3854 NNS denotes patients
T86 3855-3862 VBN denotes treated
T87 3863-3867 IN denotes with
T88 3868-3871 DT denotes the
T89 3872-3880 NN denotes anti‐IgE
T90 3881-3889 NN denotes XmAb7195
T91 3890-3900 VBG denotes containing
T92 3901-3904 DT denotes the
T93 3905-3912 NN denotes FcγRIIb
T94 3913-3922 VBG denotes enhancing
T95 3923-3929 NNP denotes “SELF”
T96 3930-3943 NNS denotes modifications
T97 3943-3944 -COMMA- denotes ,
T98 3945-3947 IN denotes as
T99 3948-3957 VBN denotes described
T100 3958-3968 RB denotes previously
T101 3971-3977 JJ denotes Immune
T102 3978-3985 NN denotes agonism
T103 3986-3993 IN denotes through
T104 3994-3998 NN denotes FcγR
T105 3999-4010 NN denotes scaffolding
T106 4011-4020 JJ denotes Agonistic
T107 4021-4025 NNS denotes mAbs
T108 4026-4032 VBP denotes induce
T109 4033-4042 NNS denotes responses
T110 4043-4045 IN denotes in
T111 4046-4052 NN denotes target
T112 4053-4058 NNS denotes cells
T113 4059-4061 IN denotes by
T114 4062-4073 VBG denotes stimulating
T115 4074-4083 NN denotes signaling
T116 4084-4086 IN denotes of
T117 4087-4092 PRP-DOLLAR- denotes their
T118 4093-4102 JJ denotes molecular
T119 4103-4109 NN denotes target
T120 4111-4120 RB denotes Typically
T121 4120-4121 -COMMA- denotes ,
T122 4122-4126 DT denotes this
T123 4127-4129 VBZ denotes is
T124 4130-4132 TO denotes to
T125 4133-4139 CC denotes either
T126 4140-4147 VB denotes enhance
T127 4148-4157 NN denotes antitumor
T128 4158-4166 NN denotes immunity
T129 4167-4169 IN denotes by
T130 4170-4178 VBG denotes engaging
T131 4179-4192 JJ denotes costimulatory
T132 4193-4202 NNS denotes molecules
T133 4203-4205 IN denotes on
T134 4206-4224 JJ denotes antigen‐presenting
T135 4225-4230 NNS denotes cells
T136 4231-4233 CC denotes or
T137 4234-4235 NN denotes T
T138 4236-4241 NNS denotes cells
T139 4242-4243 -LRB- denotes (
T140 4243-4247 FW denotes i.e.
T141 4248-4252 NN denotes CD40
T142 4252-4253 -COMMA- denotes ,
T143 4254-4259 NN denotes 4‐1BB
T144 4259-4260 -COMMA- denotes ,
T145 4261-4265 NN denotes OX40
T146 4265-4266 -RRB- denotes )
T147 4267-4269 CC denotes or
T148 4270-4277 VB denotes promote
T149 4278-4287 NN denotes apoptosis
T150 4288-4290 IN denotes by
T151 4291-4299 VBG denotes engaging
T152 4300-4305 NN denotes death
T153 4306-4315 NNS denotes receptors
T154 4316-4318 IN denotes on
T155 4319-4325 NN denotes cancer
T156 4326-4331 NNS denotes cells
T157 4332-4333 -LRB- denotes (
T158 4333-4337 FW denotes i.e.
T159 4338-4341 NN denotes DR4
T160 4341-4342 -COMMA- denotes ,
T161 4343-4346 NN denotes DR5
T162 4346-4347 -COMMA- denotes ,
T163 4348-4351 NN denotes Fas
T164 4351-4352 -RRB- denotes )
T165 4357-4360 DT denotes The
T166 4361-4365 NN denotes role
T167 4366-4368 IN denotes of
T168 4369-4373 NN denotes FcγR
T169 4374-4376 IN denotes in
T170 4377-4380 DT denotes the
T171 4381-4387 NN denotes action
T172 4388-4390 IN denotes of
T173 4391-4396 DT denotes these
T174 4397-4402 NNS denotes types
T175 4403-4405 IN denotes of
T176 4406-4410 NNS denotes mAbs
T177 4411-4418 VBZ denotes appears
T178 4419-4421 TO denotes to
T179 4422-4424 VB denotes be
T180 4425-4434 RB denotes primarily
T181 4435-4437 IN denotes as
T182 4438-4439 DT denotes a
T183 4440-4448 NN denotes scaffold
T184 4450-4457 NN denotes FcγRIIb
T185 4458-4460 VBZ denotes is
T186 4461-4466 RB denotes often
T187 4467-4470 DT denotes the
T188 4471-4482 JJ denotes predominate
T189 4483-4491 NN denotes receptor
T190 4492-4500 VBN denotes involved
T191 4501-4504 CC denotes and
T192 4505-4508 DT denotes the
T193 4509-4515 NN denotes extent
T194 4516-4518 IN denotes of
T195 4519-4522 PRP-DOLLAR- denotes its
T196 4523-4534 NN denotes involvement
T197 4535-4537 VBZ denotes is
T198 4538-4545 JJ denotes complex
T199 4547-4549 IN denotes In
T200 4550-4553 DT denotes the
T201 4554-4558 NN denotes case
T202 4559-4561 IN denotes of
T203 4562-4566 NN denotes CD40
T204 4566-4567 -COMMA- denotes ,
T205 4568-4571 DT denotes the
T206 4572-4578 NN denotes degree
T207 4579-4581 IN denotes of
T208 4582-4589 NN denotes FcγRIIb
T209 4590-4601 NN denotes scaffolding
T210 4602-4609 NN denotes potency
T211 4610-4612 VBZ denotes is
T212 4613-4619 VBN denotes linked
T213 4620-4622 TO denotes to
T214 4623-4626 DT denotes the
T215 4627-4634 NN denotes epitope
T216 4635-4643 NN denotes location
T217 4644-4646 IN denotes of
T218 4647-4650 DT denotes the
T219 4651-4660 VBG denotes targeting
T220 4661-4664 NN denotes mAb
T221 4665-4669 IN denotes with
T222 4670-4677 JJR denotes greater
T223 4678-4685 NN denotes potency
T224 4686-4690 VBN denotes seen
T225 4691-4694 IN denotes for
T226 4695-4703 NN denotes membrane
T227 4704-4712 JJ denotes proximal
T228 4713-4724 NN denotes epitopes.43
T229 4724-4725 -COMMA- denotes ,
T230 4726-4729 CD denotes 117
T231 4730-4732 PRP denotes It
T232 4733-4735 VBZ denotes is
T233 4736-4740 RB denotes also
T234 4741-4751 JJ denotes noteworthy
T235 4752-4756 IN denotes that
T236 4757-4766 VBG denotes depending
T237 4767-4769 IN denotes on
T238 4770-4773 DT denotes the
T239 4774-4781 NN denotes epitope
T240 4782-4790 NN denotes location
T241 4790-4791 -COMMA- denotes ,
T242 4792-4795 DT denotes the
T243 4796-4807 NN denotes scaffolding
T244 4808-4810 IN denotes of
T245 4811-4820 NN denotes anti‐CD40
T246 4821-4825 NNS denotes mAbs
T247 4826-4829 MD denotes may
T248 4830-4837 VB denotes convert
T249 4838-4848 NN denotes antagonist
T250 4849-4853 NNS denotes mAbs
T251 4854-4856 TO denotes to
T252 4857-4866 JJ denotes agonistic
T253 4868-4879 NN denotes Engineering
T254 4880-4882 IN denotes of
T255 4883-4886 DT denotes the
T256 4887-4891 NN denotes IgG1
T257 4892-4894 NN denotes Fc
T258 4895-4901 NN denotes region
T259 4902-4905 IN denotes for
T260 4906-4914 VBN denotes enhanced
T261 4915-4921 CC denotes and/or
T262 4922-4930 JJ denotes specific
T263 4931-4938 NN denotes binding
T264 4939-4941 TO denotes to
T265 4942-4949 NN denotes FcγRIIb
T266 4950-4953 MD denotes can
T267 4954-4961 RB denotes greatly
T268 4962-4969 VB denotes improve
T269 4970-4979 JJ denotes agonistic
T270 4980-4991 NN denotes function.72
T271 4991-4992 -COMMA- denotes ,
T272 4993-4996 CD denotes 118
T273 4996-4997 -COMMA- denotes ,
T274 4998-5001 CD denotes 119
T275 5001-5002 -COMMA- denotes ,
T276 5003-5006 CD denotes 120
T277 5007-5011 JJ denotes Such
T278 5012-5021 NNS denotes mutations
T279 5022-5029 VBD denotes induced
T280 5030-5043 RB denotes significantly
T281 5044-5051 JJR denotes greater
T282 5052-5061 JJ denotes agonistic
T283 5062-5070 NN denotes activity
T284 5071-5073 IN denotes in
T285 5074-5076 DT denotes an
T286 5077-5085 NN denotes anti‐DR5
T287 5086-5091 NN denotes model
T288 5092-5099 IN denotes through
T289 5100-5109 VBN denotes increased
T290 5110-5119 NN denotes induction
T291 5120-5122 IN denotes of
T292 5123-5132 JJ denotes apoptotic
T293 5133-5138 NN denotes death
T294 5139-5142 CC denotes and
T295 5143-5152 VBD denotes decreased
T296 5153-5158 NN denotes tumor
T297 5159-5165 NN denotes growth
T298 5166-5174 VBN denotes compared
T299 5175-5179 IN denotes with
T300 5180-5190 JJ denotes unmodified
T301 5191-5199 NN denotes IgG1.121
T302 5200-5203 DT denotes The
T303 5204-5210 NNP denotes “SELF”
T304 5211-5224 NNS denotes modifications
T305 5225-5229 WDT denotes that
T306 5230-5242 RB denotes dramatically
T307 5243-5246 CC denotes and
T308 5247-5258 RB denotes selectively
T309 5259-5267 VBP denotes increase
T310 5268-5276 NN denotes affinity
T311 5277-5280 IN denotes for
T312 5281-5288 NN denotes FcγRIIb
T313 5289-5293 VBP denotes have
T314 5294-5298 RB denotes also
T315 5299-5303 VBN denotes been
T316 5304-5308 VBN denotes used
T317 5309-5311 TO denotes to
T318 5312-5319 VB denotes enhance
T319 5320-5326 JJ denotes immune
T320 5327-5334 NN denotes agonism
T321 5335-5337 IN denotes in
T322 5338-5340 DT denotes an
T323 5341-5350 NN denotes anti‐OX40
T324 5351-5360 NN denotes model.122
T325 5361-5364 DT denotes The
T326 5365-5381 NN denotes incorporation of
T327 5382-5385 DT denotes the
T328 5386-5387 -DQS- denotes "
T329 5387-5390 NN denotes V12
T330 5390-5391 '' denotes "
T331 5392-5394 NN denotes Fc
T332 5395-5404 NNS denotes mutations
T333 5405-5409 IN denotes into
T334 5410-5414 NN denotes IgG1
T335 5415-5427 RB denotes specifically
T336 5428-5435 VBP denotes enhance
T337 5436-5443 NN denotes FcγRIIb
T338 5444-5455 NN denotes interaction
T339 5456-5464 RB denotes 200‐fold
T340 5464-5465 -COMMA- denotes ,
T341 5466-5476 VBG denotes conferring
T342 5477-5480 DT denotes the
T343 5481-5489 VBN denotes enhanced
T344 5490-5499 JJ denotes agonistic
T345 5500-5508 NN denotes activity
T346 5509-5511 IN denotes of
T347 5512-5514 DT denotes an
T348 5515-5525 NN denotes anti‐CD137
T349 5526-5534 NN denotes antibody
T350 5535-5538 CC denotes and
T351 5539-5541 DT denotes an
T352 5542-5551 NN denotes anti‐OX40
T353 5552-5559 NN denotes mAb.115
T354 5559-5560 -COMMA- denotes ,
T355 5561-5564 CD denotes 122
R0 T1 T0 arg1Of expression,The
R1 T1 T2 arg1Of expression,of
R10 T12 T10 arg1Of or,the
R100 T94 T97 arg1Of enhancing,","
R101 T94 T98 arg1Of enhancing,as
R102 T99 T98 arg2Of described,as
R103 T99 T100 arg1Of described,previously
R104 T102 T101 arg1Of agonism,Immune
R105 T102 T103 arg1Of agonism,through
R106 T105 T103 arg2Of scaffolding,through
R107 T105 T104 arg1Of scaffolding,FcγR
R108 T107 T106 arg1Of mAbs,Agonistic
R109 T107 T108 arg1Of mAbs,induce
R11 T11 T12 arg1Of “sweeping”,or
R110 T109 T108 arg2Of responses,induce
R111 T109 T110 arg1Of responses,in
R112 T112 T110 arg2Of cells,in
R113 T112 T111 arg1Of cells,target
R114 T108 T113 arg1Of induce,by
R115 T114 T113 arg2Of stimulating,by
R116 T107 T114 arg1Of mAbs,stimulating
R117 T115 T114 arg2Of signaling,stimulating
R118 T115 T116 arg1Of signaling,of
R119 T119 T116 arg2Of target,of
R12 T13 T12 arg2Of removal,or
R120 T119 T117 arg1Of target,their
R121 T119 T118 arg1Of target,molecular
R122 T123 T120 arg1Of is,Typically
R123 T123 T121 arg1Of is,","
R124 T122 T123 arg1Of this,is
R125 T147 T123 arg2Of or,is
R126 T147 T124 arg1Of or,to
R127 T147 T125 arg1Of or,either
R128 T128 T126 arg2Of immunity,enhance
R129 T128 T127 arg1Of immunity,antitumor
R13 T12 T14 arg1Of or,of
R130 T126 T129 arg1Of enhance,by
R131 T130 T129 arg2Of engaging,by
R132 T132 T130 arg2Of molecules,engaging
R133 T132 T131 arg1Of molecules,costimulatory
R134 T132 T133 arg1Of molecules,on
R135 T136 T133 arg2Of or,on
R136 T135 T134 arg1Of cells,antigen‐presenting
R137 T135 T136 arg1Of cells,or
R138 T138 T136 arg2Of cells,or
R139 T138 T137 arg1Of cells,T
R14 T17 T14 arg2Of complexes,of
R140 T136 T139 arg1Of or,(
R141 T142 T139 arg2Of ",",(
R142 T146 T139 arg3Of ),(
R143 T142 T140 arg1Of ",",i.e.
R144 T141 T142 arg1Of CD40,","
R145 T143 T142 arg2Of 4‐1BB,","
R146 T142 T144 arg1Of ",",","
R147 T145 T144 arg2Of OX40,","
R148 T126 T147 arg1Of enhance,or
R149 T148 T147 arg2Of promote,or
R15 T17 T15 arg1Of complexes,small
R150 T149 T148 arg2Of apoptosis,promote
R151 T148 T150 arg1Of promote,by
R152 T151 T150 arg2Of engaging,by
R153 T153 T151 arg2Of receptors,engaging
R154 T153 T152 arg1Of receptors,death
R155 T153 T154 arg1Of receptors,on
R156 T156 T154 arg2Of cells,on
R157 T156 T155 arg1Of cells,cancer
R158 T156 T157 arg1Of cells,(
R159 T159 T157 arg2Of DR4,(
R16 T17 T16 arg1Of complexes,immune
R160 T164 T157 arg3Of ),(
R161 T159 T158 arg1Of DR4,i.e.
R162 T159 T160 arg1Of DR4,","
R163 T161 T160 arg2Of DR5,","
R164 T159 T162 arg1Of DR4,","
R165 T163 T162 arg2Of Fas,","
R166 T166 T165 arg1Of role,The
R167 T166 T167 arg1Of role,of
R168 T168 T167 arg2Of FcγR,of
R169 T166 T169 arg1Of role,in
R17 T6 T18 arg1Of and,has
R170 T171 T169 arg2Of action,in
R171 T171 T170 arg1Of action,the
R172 T171 T172 arg1Of action,of
R173 T174 T172 arg2Of types,of
R174 T174 T173 arg1Of types,these
R175 T174 T175 arg1Of types,of
R176 T176 T175 arg2Of mAbs,of
R177 T166 T177 arg1Of role,appears
R178 T179 T177 arg2Of be,appears
R179 T179 T178 arg1Of be,to
R18 T19 T18 arg2Of opened,has
R180 T166 T179 arg1Of role,be
R181 T181 T179 arg2Of as,be
R182 T181 T180 arg1Of as,primarily
R183 T166 T181 arg1Of role,as
R184 T183 T181 arg2Of scaffold,as
R185 T183 T182 arg1Of scaffold,a
R186 T184 T185 arg1Of FcγRIIb,is
R187 T189 T185 arg2Of receptor,is
R188 T185 T186 arg1Of is,often
R189 T189 T187 arg1Of receptor,the
R19 T6 T19 arg1Of and,opened
R190 T189 T188 arg1Of receptor,predominate
R191 T189 T190 arg2Of receptor,involved
R192 T185 T191 arg1Of is,and
R193 T197 T191 arg2Of is,and
R194 T193 T192 arg1Of extent,the
R195 T193 T194 arg1Of extent,of
R196 T196 T194 arg2Of involvement,of
R197 T196 T195 arg1Of involvement,its
R198 T193 T197 arg1Of extent,is
R199 T198 T197 arg2Of complex,is
R2 T3 T2 arg2Of FcγRIIb,of
R20 T22 T19 arg2Of possibilities,opened
R200 T193 T198 arg1Of extent,complex
R201 T212 T199 arg1Of linked,In
R202 T201 T199 arg2Of case,In
R203 T201 T200 arg1Of case,the
R204 T201 T202 arg1Of case,of
R205 T203 T202 arg2Of CD40,of
R206 T212 T204 arg1Of linked,","
R207 T206 T205 arg1Of degree,the
R208 T206 T207 arg1Of degree,of
R209 T210 T207 arg2Of potency,of
R21 T19 T20 arg1Of opened,up
R210 T210 T208 arg1Of potency,FcγRIIb
R211 T210 T209 arg1Of potency,scaffolding
R212 T206 T211 arg1Of degree,is
R213 T212 T211 arg2Of linked,is
R214 T232 T211 modOf is,is
R215 T206 T212 arg2Of degree,linked
R216 T212 T213 arg1Of linked,to
R217 T216 T213 arg2Of location,to
R218 T216 T214 arg1Of location,the
R219 T216 T215 arg1Of location,epitope
R22 T22 T21 arg1Of possibilities,new
R220 T216 T217 arg1Of location,of
R221 T219 T217 arg2Of targeting,of
R222 T219 T218 arg1Of targeting,the
R223 T218 T219 arg1Of the,targeting
R224 T220 T219 arg2Of mAb,targeting
R225 T219 T221 arg1Of targeting,with
R226 T223 T221 arg2Of potency,with
R227 T223 T222 arg1Of potency,greater
R228 T223 T224 arg2Of potency,seen
R229 T224 T225 arg1Of seen,for
R23 T22 T23 arg1Of possibilities,for
R230 T228 T225 arg2Of epitopes.43,for
R231 T228 T226 arg1Of epitopes.43,membrane
R232 T228 T227 arg1Of epitopes.43,proximal
R233 T216 T229 arg1Of location,","
R234 T230 T229 arg2Of 117,","
R235 T248 T231 arg1Of convert,It
R236 T248 T232 arg1Of convert,is
R237 T234 T232 arg2Of noteworthy,is
R238 T232 T233 arg1Of is,also
R239 T248 T234 arg1Of convert,noteworthy
R24 T25 T23 arg2Of application,for
R240 T248 T235 arg1Of convert,that
R241 T248 T236 arg1Of convert,depending
R242 T237 T236 arg2Of on,depending
R243 T240 T237 arg2Of location,on
R244 T240 T238 arg1Of location,the
R245 T240 T239 arg1Of location,epitope
R246 T248 T241 arg1Of convert,","
R247 T243 T242 arg1Of scaffolding,the
R248 T243 T244 arg1Of scaffolding,of
R249 T246 T244 arg2Of mAbs,of
R25 T25 T24 arg1Of application,the
R250 T246 T245 arg1Of mAbs,anti‐CD40
R251 T243 T247 arg1Of scaffolding,may
R252 T248 T247 arg2Of convert,may
R253 T243 T248 arg1Of scaffolding,convert
R254 T250 T248 arg2Of mAbs,convert
R255 T250 T249 arg1Of mAbs,antagonist
R256 T248 T251 arg1Of convert,to
R257 T252 T251 arg2Of agonistic,to
R258 T253 T254 arg1Of Engineering,of
R259 T258 T254 arg2Of region,of
R26 T25 T26 arg1Of application,of
R260 T258 T255 arg1Of region,the
R261 T258 T256 arg1Of region,IgG1
R262 T258 T257 arg1Of region,Fc
R263 T258 T259 arg1Of region,for
R264 T263 T259 arg2Of binding,for
R265 T263 T260 arg1Of binding,enhanced
R266 T260 T261 arg1Of enhanced,and/or
R267 T262 T261 arg2Of specific,and/or
R268 T263 T262 arg1Of binding,specific
R269 T263 T264 arg1Of binding,to
R27 T30 T26 arg2Of or,of
R270 T265 T264 arg2Of FcγRIIb,to
R271 T253 T266 arg1Of Engineering,can
R272 T268 T266 arg2Of improve,can
R273 T268 T267 arg1Of improve,greatly
R274 T253 T268 arg1Of Engineering,improve
R275 T270 T268 arg2Of function.72,improve
R276 T270 T269 arg1Of function.72,agonistic
R277 T270 T271 arg1Of function.72,","
R278 T272 T271 arg2Of 118,","
R279 T270 T273 arg1Of function.72,","
R28 T29 T27 arg1Of Antibodies,FcγRIIb‐enhancing
R280 T274 T273 arg2Of 119,","
R281 T268 T275 arg1Of improve,","
R282 T294 T275 arg2Of and,","
R283 T278 T276 arg1Of mutations,120
R284 T278 T277 arg1Of mutations,Such
R285 T278 T279 arg1Of mutations,induced
R286 T283 T279 arg2Of activity,induced
R287 T281 T280 arg1Of greater,significantly
R288 T283 T281 arg1Of activity,greater
R289 T283 T282 arg1Of activity,agonistic
R29 T29 T28 arg1Of Antibodies,modifications.17
R290 T279 T284 arg1Of induced,in
R291 T287 T284 arg2Of model,in
R292 T287 T285 arg1Of model,an
R293 T287 T286 arg1Of model,anti‐DR5
R294 T279 T288 arg1Of induced,through
R295 T290 T288 arg2Of induction,through
R296 T290 T289 arg2Of induction,increased
R297 T290 T291 arg1Of induction,of
R298 T293 T291 arg2Of death,of
R299 T293 T292 arg1Of death,apoptotic
R3 T1 T4 arg1Of expression,on
R30 T29 T30 arg1Of Antibodies,or
R300 T279 T294 arg1Of induced,and
R301 T295 T294 arg2Of decreased,and
R302 T278 T295 arg1Of mutations,decreased
R303 T297 T295 arg2Of growth,decreased
R304 T297 T296 arg1Of growth,tumor
R305 T295 T298 arg1Of decreased,compared
R306 T299 T298 arg2Of with,compared
R307 T301 T299 arg2Of IgG1.121,with
R308 T301 T300 arg1Of IgG1.121,unmodified
R309 T304 T302 arg1Of modifications,The
R31 T33 T30 arg2Of proteins,or
R310 T304 T303 arg1Of modifications,“SELF”
R311 T304 T305 arg1Of modifications,that
R312 T309 T306 arg1Of increase,dramatically
R313 T306 T307 arg1Of dramatically,and
R314 T308 T307 arg2Of selectively,and
R315 T309 T308 arg1Of increase,selectively
R316 T304 T309 arg1Of modifications,increase
R317 T310 T309 arg2Of affinity,increase
R318 T310 T311 arg1Of affinity,for
R319 T312 T311 arg2Of FcγRIIb,for
R32 T33 T31 arg1Of proteins,Fc
R320 T304 T313 arg1Of modifications,have
R321 T316 T313 arg2Of used,have
R322 T316 T314 arg1Of used,also
R323 T304 T315 arg1Of modifications,been
R324 T316 T315 arg2Of used,been
R325 T304 T316 arg2Of modifications,used
R326 T318 T316 arg3Of enhance,used
R327 T318 T317 arg1Of enhance,to
R328 T304 T318 arg1Of modifications,enhance
R329 T301 T318 arg2Of IgG1.121,enhance
R33 T33 T32 arg1Of proteins,fusion
R330 T320 T319 arg1Of agonism,immune
R331 T299 T320 arg1Of with,agonism
R332 T320 T321 arg1Of agonism,in
R333 T324 T321 arg2Of model.122,in
R334 T324 T322 arg1Of model.122,an
R335 T324 T323 arg1Of model.122,anti‐OX40
R336 T326 T325 arg1Of incorporation of,The
R337 T336 T326 arg1Of enhance,incorporation of
R338 T332 T327 arg1Of mutations,the
R339 T332 T328 arg1Of mutations,""""
R34 T22 T34 arg1Of possibilities,","
R340 T332 T329 arg1Of mutations,V12
R341 T332 T330 arg1Of mutations,""""
R342 T332 T331 arg1Of mutations,Fc
R343 T332 T333 arg1Of mutations,into
R344 T334 T333 arg2Of IgG1,into
R345 T336 T335 arg1Of enhance,specifically
R346 T332 T336 arg1Of mutations,enhance
R347 T338 T336 arg2Of interaction,enhance
R348 T338 T337 arg1Of interaction,FcγRIIb
R349 T336 T339 arg1Of enhance,200‐fold
R35 T37 T35 arg1Of MOA,whose
R350 T336 T340 arg1Of enhance,","
R351 T332 T341 arg1Of mutations,conferring
R352 T350 T341 arg2Of and,conferring
R353 T336 T341 modOf enhance,conferring
R354 T345 T342 arg1Of activity,the
R355 T345 T343 arg2Of activity,enhanced
R356 T345 T344 arg1Of activity,agonistic
R357 T345 T346 arg1Of activity,of
R358 T349 T346 arg2Of antibody,of
R359 T349 T347 arg1Of antibody,an
R36 T22 T35 arg2Of possibilities,whose
R360 T349 T348 arg1Of antibody,anti‐CD137
R361 T345 T350 arg1Of activity,and
R362 T353 T350 arg2Of mAb.115,and
R363 T353 T351 arg1Of mAb.115,an
R364 T353 T352 arg1Of mAb.115,anti‐OX40
R365 T353 T354 arg1Of mAb.115,","
R366 T355 T354 arg2Of 122,","
R37 T37 T36 arg1Of MOA,primary
R38 T37 T38 arg1Of MOA,is
R39 T40 T38 arg2Of neutralization,is
R4 T5 T4 arg2Of LSEC,on
R40 T40 T39 arg1Of neutralization,the
R41 T40 T41 arg1Of neutralization,of
R42 T43 T41 arg2Of molecules,of
R43 T43 T42 arg1Of molecules,soluble
R44 T45 T44 arg1Of as,such
R45 T43 T45 arg1Of molecules,as
R46 T47 T45 arg2Of or,as
R47 T46 T47 arg1Of IgE,or
R48 T48 T47 arg2Of cytokines,or
R49 T38 T49 arg1Of is,","
R5 T1 T6 arg1Of expression,and
R50 T50 T49 arg2Of are,","
R51 T37 T50 arg1Of MOA,are
R52 T53 T50 arg2Of candidates,are
R53 T52 T51 arg1Of attractive,particularly
R54 T53 T52 arg1Of candidates,attractive
R55 T53 T54 arg1Of candidates,for
R56 T56 T54 arg2Of approach,for
R57 T56 T55 arg1Of approach,this
R58 T57 T58 arg1Of Proof‐of‐concept,for
R59 T60 T58 arg2Of strategy,for
R6 T8 T6 arg2Of action,and
R60 T60 T59 arg1Of strategy,this
R61 T57 T61 arg1Of Proof‐of‐concept,has
R62 T63 T61 arg2Of demonstrated,has
R63 T57 T62 arg1Of Proof‐of‐concept,been
R64 T63 T62 arg2Of demonstrated,been
R65 T57 T63 arg2Of Proof‐of‐concept,demonstrated
R66 T63 T64 arg1Of demonstrated,in
R67 T66 T64 arg2Of models.48,in
R68 T66 T65 arg1Of models.48,experimental
R69 T66 T67 arg1Of models.48,Indeed
R7 T8 T7 arg1Of action,its
R70 T63 T68 arg1Of demonstrated,","
R71 T71 T68 arg2Of be,","
R72 T69 T70 arg1Of this,may
R73 T71 T70 arg2Of be,may
R74 T69 T71 arg1Of this,be
R75 T74 T71 arg2Of component,be
R76 T74 T72 arg1Of component,a
R77 T74 T73 arg1Of component,significant
R78 T74 T75 arg1Of component,of
R79 T78 T75 arg2Of disappearance,of
R8 T8 T9 arg1Of action,in
R80 T78 T76 arg1Of disappearance,the
R81 T78 T77 arg1Of disappearance,rapid
R82 T78 T79 arg1Of disappearance,of
R83 T80 T79 arg2Of IgE,of
R84 T80 T81 arg1Of IgE,from
R85 T83 T81 arg2Of circulation,from
R86 T83 T82 arg1Of circulation,the
R87 T83 T84 arg1Of circulation,of
R88 T85 T84 arg2Of patients,of
R89 T85 T86 arg2Of patients,treated
R9 T12 T9 arg2Of or,in
R90 T86 T87 arg1Of treated,with
R91 T90 T87 arg2Of XmAb7195,with
R92 T90 T88 arg1Of XmAb7195,the
R93 T90 T89 arg1Of XmAb7195,anti‐IgE
R94 T90 T91 arg1Of XmAb7195,containing
R95 T93 T91 arg2Of FcγRIIb,containing
R96 T93 T92 arg1Of FcγRIIb,the
R97 T93 T94 arg1Of FcγRIIb,enhancing
R98 T96 T94 arg2Of modifications,enhancing
R99 T96 T95 arg1Of modifications,“SELF”